Both macro- and microeconomic aspects of biotechnology are discussed in this book for biologists studying microbiology, biochemistry and genetics. It explains economics and accounting procedures from first principles and assumes no prior knowledge of these areas. The author works on developing new biotechnological projects. He draws extensively on his own experience and brings together the factors which determine commercial reasoning towards biotechnology in areas such as markets, project selection, costing and capital investment. His subjects include market analysis, fermentation, enzyme technology, genetic engineering and many others; they are all tied together by a common framework of industrial and technological development.

The tremendous progress in biology over the last half century - from Watson and Crick's elucidation of the structure of DNA to today's astonishing, rapid progress in the field of synthetic biology - has positioned us for significant innovation in chemical production. New bio-based chemicals, improved public health through improved drugs and diagnostics, and biofuels that reduce our dependency on oil are all results of research and innovation in the biological sciences. In the past decade, we have witnessed major advances made possible by biotechnology in areas such as rapid, low-cost DNA sequencing, metabolic engineering, and high-throughput screening. The manufacturing of chemicals using biological synthesis and engineering could expand even faster. A proactive strategy - implemented through the development of a technical roadmap similar to those that enabled sustained growth in the semiconductor industry and our explorations of space - is needed if we are to realize the widespread benefits of accelerating the industrialization of biology. Industrialization of Biology presents such a roadmap to achieve key technical milestones for chemical manufacturing through biological routes. This report examines the technical, economic, and societal factors that limit the adoption of bioprocessing in the chemical industry today and which, if surmounted, would markedly accelerate the advanced manufacturing of chemicals via industrial biotechnology. Working at the interface of synthetic chemistry, metabolic engineering, molecular biology, and synthetic biology, Industrialization of Biology identifies key technical goals for next-generation chemical manufacturing, then identifies the gaps in knowledge, tools, techniques, and systems required to meet those goals, and targets and timelines for achieving them. This report also considers the skills necessary to accomplish the roadmap goals, and what training opportunities are required to produce the cadre of skilled scientists and engineers needed.

The commercialization of biotechnology has resulted in a search for biological resources for the purposes of increasing food productivity, medicinal applications, and energy production. This book discusses the role of biological, ecological, environmental, ethical, and economic issues in the interaction between biotechnology and biodiversity.

Around the world, many countries are increasing efforts to promote biomass production for industrial uses including biofuels and bio-products such as chemicals and bio-plastic. Against a backdrop of lively public debate on sustainability, bioenergy wields both positive and negative impacts upon a variety of environmental and socio-economic issues. These include property rights, labor conditions, social welfare, economic wealth, poverty reduction and more. This book discusses the issues and impacts of bioenergy, taking into account the local and regional framework under which bioenergy is produced, touching upon educational level, cultural aspects, the history and economies of the producing countries and an array of policies including environmental and social targets. The book surveys and analyzes global bioenergy production from a number of perspectives. The authors illustrate the complexity of interrelated topics in the bioenergy value chain, ranging from agriculture to conversion processes, as well as from social implications to environmental effects. It goes on to offer insight on future challenges associated with the expected boom of a global bio-based economy, which contributes to the paradigm shift from a fossil-based to a biomass and renewable energy-based economy. The expert contributors include researchers, investors, policy makers, representatives from NGOs and other stakeholders, from Europe, Africa, Asia and Latin America. Their contributions build upon the results of the Global-Bio-Pact project on “Global Assessment of Biomass and Bio-product Impacts on Socio-economics and Sustainability,” which was supported by the European Commission in its 7th Framework Program for Research and Technological Development, conducted from February 2010 to January 2013. The book benefits policy makers, scientists and NGO staffers working in the fields of agriculture, forestry, biotechnology and energy.

Genetically engineered (GE) crops were first introduced commercially in the 1990s. After two decades of production, some groups and individuals remain critical of the technology based on their concerns about possible adverse effects on human health, the environment, and ethical considerations. At the same time, others are concerned that the technology is not reaching its potential to improve human health and the environment because of stringent regulations and reduced public funding to develop products offering more benefits to society. While the debate about these and other questions related to the genetic engineering techniques of the first 20 years goes on, emerging genetic-engineering technologies are adding new complexities to the conversation. Genetically Engineered Crops builds on previous related Academies reports published between 1987 and 2010 by undertaking a retrospective examination of the purported positive and adverse effects of GE crops and to anticipate what emerging genetic-engineering technologies hold for the future. This report indicates where there are uncertainties about the economic, agronomic, health, safety, or other impacts of GE crops and food, and makes recommendations to fill gaps in safety assessments, increase regulatory clarity, and improve innovations in and access to GE technology.

Using economic models and empirical analysis, this volume examines a wide range of agricultural and biofuel policy issues and their effects on American agricultural and related agrarian insurance markets. Beginning with a look at the distribution of funds by insurance programs—created to support farmers but often benefiting crop processors instead—the book then examines the demand for biofuel and the effects of biofuel policies on agricultural price uncertainty. Also discussed are genetically engineered crops, which are assuming an increasingly important role in arbitrating tensions between energy production, environmental protection, and the global food supply. Other contributions discuss the major effects of genetic engineering on worldwide food markets. By addressing some of the most challenging topics at the intersection of agriculture and biotechnology, this volume informs crucial debates.

This book includes 6 chapters examining the relevance of transgenic crops in food production, prices and the environment. It initially describes the historical evolution of biotechnology and defines key terms, before moving on to explore transgenic technology and food regime concepts. It analyses genetically modified organism (GMO) policy as part of overall agrarian policy, considering neoregulation in the USA, the EU, Brazil, Russia, China, India, South Africa and Serbia, as well as discussing agricultural performance, support and trade relations. The effect of transgenic food production on world food prices is also examined, along with food security at global and regional levels, and the links between GMOs and world hunger. The environmental implications of transgenic technology are considered through analysis of pesticide and fertilizer usage and efficiency, and pesticide consumption in GMO and non-GMO producing countries. Finally, the book considers the entry of transgenic ingredients into the food chain and lists GMOs approved for use in foods and products contaminated with unapproved GMOs. The key features of this book include: a detailed analysis of economic data; a comparison of international trends, including BRICS countries (Brazil, Russia, India, China and South Africa) and Serbia; evaluation of environmental and food security implications; and glossary of important terms. This book is intended for a wide range of professionals and researchers whose interests relate to all aspects of the global food system, including policy makers, policy advisers and analysts, NGOs, students and other interest groups.

Focusing on the period between the 1970s and the present, Life as Surplus is a pointed and important study of the relationship between politics, economics, science, and cultural values in the United States today. Melinda Cooper demonstrates that the history of biotechnology cannot be understood without taking into account the simultaneous rise of neoliberalism as a political force and an economic policy. From the development of recombinant DNA technology in the 1970s to the second Bush administration's policies on stem cell research, Cooper connects the utopian polemic of free-market capitalism with growing internal contradictions of the commercialized life sciences. The biotech revolution relocated economic production at the genetic, microbial, and cellular level. Taking as her point of departure the assumption that life has been drawn into the circuits of value creation, Cooper underscores the relations between scientific, economic, political, and social practices. In penetrating analyses of Reagan-era science policy, the militarization of the life sciences, HIV politics, pharmaceutical imperialism, tissue engineering, stem cell science, and the pro-life movement, the author examines the speculative impulses that have animated the growth of the bioeconomy. At the very core of the new post-industrial economy is the transformation of biological life into surplus value. Life as Surplus offers a clear assessment of both the transformative, therapeutic dimensions of the contemporary life sciences and the violence, obligation, and debt servitude crystallizing around the emerging bioeconomy.

Economists, psychologists, and marketers are interested in determining the monetary value people place on non-market goods for a variety of reasons: to carry out cost-benefit analysis, to determine the welfare effects of technological innovation or public policy, to forecast new product success, and to understand individual and consumer behavior. Unfortunately, many currently available techniques for eliciting individuals' values suffer from a serious problem in that they involve asking individuals hypothetical questions about intended behavior. Experimental auctions circumvent this problem because they involve individuals exchanging real money for real goods in an active market. This represents a promising means for eliciting non-market values. Lusk and Shogren provide a comprehensive guide to the theory and practice of experimental auctions. It will be a valuable resource to graduate students, practitioners and researchers concerned with the design and utilization of experimental auctions in applied economic and marketing research.

Between 1973 and 2016, the ways to manipulate DNA to endow new characteristics in an organism (that is, biotechnology) have advanced, enabling the development of products that were not previously possible. What will the likely future products of biotechnology be over the next 5â€"10 years? What scientific capabilities, tools, and/or expertise may be needed by the regulatory agencies to ensure they make efficient and sound evaluations of the likely future products of biotechnology? Preparing for Future Products of Biotechnology analyzes the future landscape of biotechnology products and seeks to inform forthcoming policy making. This report identifies potential new risks and frameworks for risk assessment and areas in which the risks or lack of risks relating to the products of biotechnology are well understood.